Robert Kridel
Overview
Explore the profile of Robert Kridel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2845
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kridel R
Korean J Intern Med
. 2025 Feb;
PMID: 39987895
Follicular lymphoma (FL) is the most common type of indolent lymphoma, and the prognosis is favorable for most patients. However, FL remains generally incurable, and relapse is common. Patients are...
2.
Abeyakoon C, Ting E, Khan S, Maganti M, Bhella S, Crump M, et al.
Leuk Lymphoma
. 2025 Feb;
:1-5.
PMID: 39985180
No abstract available.
3.
Sabatini P, Ta R, Peralta M, Anderson M, Khan S, Belcastro R, et al.
Arch Pathol Lab Med
. 2025 Jan;
PMID: 39786946
Context.—: Small biopsies are used for histologic, immunophenotypic, cytogenetic, molecular genetic, and other ancillary studies. Occasionally, this diagnostic tissue is exhausted before molecular testing can be performed. Objective.—: To investigate...
4.
Strati P, Agajanian R, Lossos I, Coleman M, Kridel R, Wood A, et al.
Br J Haematol
. 2024 Dec;
206(3):887-898.
PMID: 39667721
Patients with relapsed/refractory (R/R) follicular lymphoma (FL) have limited effective treatment options. Bruton tyrosine kinase inhibitors (BTKis) increase the anti-tumoural phenotype of tumour-associated macrophages, providing rationale to combine them with...
5.
MacManus M, Seymour J, Tsang H, Fisher R, Keane C, Sabdia M, et al.
EBioMedicine
. 2024 Dec;
110:105468.
PMID: 39631145
Background: We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. Methods:...
6.
Enemark M, Hemmingsen J, Jensen M, Kridel R, Ludvigsen M
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39456961
Follicular lymphoma (FL) is the most prevalent indolent B-cell lymphoma entity, often characterized by the t(14;18) translocation. The malignancy represents a clinically and biologically highly heterogeneous disease. Most patients have...
7.
Hemmingsen J, Enemark M, Sorensen E, Lauridsen K, Hamilton-Dutoit S, Kridel R, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409899
Follicular lymphoma (FL) is characterized by an indolent nature and generally favorable prognosis, yet poses a particular clinical challenge, since disease progression is observed in a notable subset of patients....
8.
Chavoshi M, Mirshahvalad S, Kohan A, Ortega C, Metser U, Farag A, et al.
Clin Nucl Med
. 2024 Sep;
50(1):e7-e16.
PMID: 39259697
Purpose: The aims of this study were to perform a comprehensive review and meta-analyses and to report pooled diagnostic results on CXCR4-targeted PET, particularly considering detection, visualization, and prognostication. Patients...
9.
He M, Tong K, Liu T, Whittaker Hawkins R, Shelton V, Zeng Y, et al.
Leukemia
. 2024 Aug;
38(10):2210-2224.
PMID: 39117798
Despite selective HDAC3 inhibition showing promise in a subset of lymphomas with CREBBP mutations, wild-type tumors generally exhibit resistance. Here, using unbiased genome-wide CRISPR screening, we identify GNAS knockout (KO)...
10.
Shelton V, Detroja R, Liu T, Isaev K, Silva A, Passerini V, et al.
Blood Cancer J
. 2024 Aug;
14(1):128.
PMID: 39112453
Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes...